Use of PARP inhibitors in prostate cancer: from specific to broader application

Use of PARP inhibitors in prostate cancer: from specific to broader application

Prostate cancer (PC) is one of the major health issues of elderly men in the word. It is showed that there were approximately 1.414 million patients with PC in 2020 worldwide, with a high mortality rate in metastatic cases. In the present choices of treatment in PC, androgen deprivation therapy has...

Full description

Bibliographic Details
Main Authors:	Zhenting Zhang, Lei Diao, Chao Zhang, Feifei Wang, Xin Guan, Xin Yao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Endocrinology
Subjects:	prostate cancer PARP inhibitor DNA damage response and repair novel hormonal therapy metastatic prostate cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1164067/full

Similar Items

PARP inhibitors in metastatic prostate cancer
by: Amy K. Taylor, et al.
Published: (2023-04-01)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
by: Jacob J. Adashek, et al.
Published: (2019-08-01)

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
by: Diego Teyssonneau, et al.
Published: (2022-03-01)

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
by: Ciara S. McNevin, et al.
Published: (2022-09-01)

The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
by: А. А. Gritskevich, et al.
Published: (2021-06-01)

Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer—Where Are We Now?
by: Arpit Rao, et al.
Published: (2022-02-01)

Advances in PARP Inhibitors for Prostate Cancer
by: Steven Tisseverasinghe, et al.
Published: (2023-03-01)

New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
by: Gaetano Aurilio, et al.
Published: (2020-06-01)

Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review)
by: Inés Rivero Belenchón, et al.
Published: (2023-08-01)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
by: Nizialek E, et al.
Published: (2020-09-01)

PARP Inhibitors: A New Horizon for Patients with Prostate Cancer
by: Belén Congregado, et al.
Published: (2022-06-01)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
by: Andrisha-Jade Inderjeeth, et al.
Published: (2022-11-01)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Albert Jang, et al.
Published: (2020-11-01)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
by: Peter H. J. Slootbeek, et al.
Published: (2023-05-01)

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer
by: Hongjie Chen, et al.
Published: (2023-10-01)

Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches
by: Catherine Handy Marshall, et al.
Published: (2020-01-01)

PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview
by: Islam Kourampi, et al.
Published: (2023-01-01)

BRCA2 and Other DDR Genes in Prostate Cancer
by: Paz Nombela, et al.
Published: (2019-03-01)

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
by: Stergios Boussios, et al.
Published: (2022-08-01)

PARP Inhibitors in Prostate and Urothelial Cancers
by: Rohan Garje, et al.
Published: (2020-02-01)

Roles of the PARP Inhibitor in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment
by: Takahiro Inoue, et al.
Published: (2023-05-01)

Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
by: Ali Divan, et al.
Published: (2020-04-01)

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
by: Inês Costa, et al.
Published: (2022-05-01)

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
by: Sidrah Shah, et al.
Published: (2021-11-01)

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
by: Maddison Rose, et al.
Published: (2020-09-01)

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
by: Elizabeth K. Lee, et al.
Published: (2020-07-01)

Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?
by: Alessandro Sciarra, et al.
Published: (2023-08-01)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib
by: De Felice F, et al.
Published: (2017-03-01)

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach
by: Mankgopo M. Kgatle, et al.
Published: (2021-04-01)

Exosome‐derived circTFDP2 promotes prostate cancer progression by preventing PARP1 from caspase‐3‐dependent cleavage
by: Lifeng Ding, et al.
Published: (2023-01-01)

Management of Advanced Prostate Cancer in the Precision Oncology Era
by: Claire M. Gillette, et al.
Published: (2023-04-01)

A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy
by: Shah Ashish P., et al.
Published: (2018-03-01)

Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
by: Aruni Ghose, et al.
Published: (2021-09-01)

Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance
by: Maxime Cahuzac, et al.
Published: (2022-08-01)

PARP Inhibitors Resistance: Mechanisms and Perspectives
by: Elena Giudice, et al.
Published: (2022-03-01)

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
by: Jingsong Zhang
Published: (2014-06-01)

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations
by: Wu MS, et al.
Published: (2022-11-01)

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: Kan Wu, et al.
Published: (2021-12-01)

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
by: Linglong Yin, et al.
Published: (2018-07-01)

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
by: Abdullah Alhusaini, et al.
Published: (2021-08-01)